Vimseltinib

The FDA granted priority review to vimseltinib for treating tenosynovial giant cell tumor (TGCT), with a decision by Feb 17, 2025. Supported by phase 3 MOTION study data, vimseltinib showed a 40% overall response rate vs 0% for placebo, with significant improvements in secondary endpoints and a manageable safety profile.

FDA grants priority review to vimseltinib for TGCT treatment, with a PDUFA target of February 17, 2025. Supported by phase 3 MOTION study data, vimseltinib showed a 40% ORR vs 0% placebo, significant clinical improvements, and manageable safety profile.

The Tenosynovial Giant Cell Tumors (TSGCTs) market, valued at approximately USD 300 million in 2023, is expected to grow significantly by 2034. Key developments include SynOx Therapeutics securing USD 75 million for emactuzumab's Phase 3 trials. The market is driven by increasing prevalence, awareness, and the launch of new therapies like Pexidartinib and vimseltinib.

DelveInsight's report on Tenosynovial Giant Cell Tumors (TSGCTs) forecasts market growth to 2034, highlighting epidemiology, treatment trends, and key therapies. The market, valued at USD 300 million in 2023, is driven by increasing prevalence and new therapies like emactuzumab. Localized TGCT cases dominate, with significant growth expected in the 7MM.